Oncotelic and Sapu Nano to Present Deciparticle Platform at BIO 2026

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that CEO Vuong Trieu will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego. This ultra-small nanomedicine platform, utilizing proprietary amphiphilic polymer systems, forms sub-20 nanometer particles designed to enable intravenous administration of highly water-insoluble therapeutics, primarily targeting oncology and other therapeutic areas. The presentation will highlight progress across multiple Deciparticle(TM) programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. Additionally, the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI(TM) platform will be showcased.

Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC. BioMedWire ("BMW") is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and a full array of tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.